Blood test may guide breast cancer therapy, reducing chemo need
NCT ID NCT07366112
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This phase 2 trial tests a personalized approach for early-stage, hormone receptor-positive breast cancer. Participants receive a combination of CDK4/6 inhibitors and endocrine therapy before surgery. A blood test (ctDNA) is used to monitor tumor DNA and may help decide if chemotherapy can be safely avoided. The study aims to see if this strategy improves outcomes and reduces unnecessary treatment.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
CDK4/6 inhibitor combined with endocrine therapy
What this could lead to
If successful, this could help personalize breast cancer treatment, potentially allowing some patients to avoid chemotherapy based on ctDNA results.
What could go wrong
This is an early phase 2 trial with only 158 participants, so results may not apply to all patients. The approach is complex and may not improve outcomes or reduce side effects as hoped.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for EARLY-STAGE BREAST CANCER are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••